Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-26 @ 4:14 AM
Study NCT ID:
NCT05433194
Status:
UNKNOWN
Last Update Posted:
2023-02-08
First Post:
2022-06-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
Sponsor:
Suzhou Abogen Biosciences Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-22
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-08-25
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-16
First Submit QC Date:
None
Study First Post Date:
2022-06-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-06
Last Update Post Date:
2023-02-08
Last Update Post Date Type:
ACTUAL